Adamis Pharma Valuation
| ADMPDelisted Stock | USD 1.74 0.24 12.12% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Adamis Pharma shows a prevailing Real Value of $1.65 per share. The current price of the firm is $1.74. Our model approximates the value of Adamis Pharma from analyzing the firm fundamentals such as return on equity of -7.85, and Operating Margin of (3.74) % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Adamis Pharma's price fluctuation is very steady at this time. Calculation of the real value of Adamis Pharma is based on 3 months time horizon. Increasing Adamis Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Adamis Pharma's intrinsic value may or may not be the same as its current market price of 1.74, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.74 | Real 1.65 | Hype 1.74 | Naive 1.76 |
The intrinsic value of Adamis Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Adamis Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Adamis Pharma helps investors to forecast how Adamis stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Adamis Pharma more accurately as focusing exclusively on Adamis Pharma's fundamentals will not take into account other important factors: Adamis Pharma Total Value Analysis
Adamis Pharma is presently expected to have valuation of 7.28 M with market capitalization of 7.25 M, debt of 342.56 K, and cash on hands of 8.88 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Adamis Pharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
7.28 M | 7.25 M | 342.56 K | 8.88 M |
Adamis Pharma Investor Information
About 17.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 10.14. Adamis Pharma had not issued any dividends in recent years. The entity had 1:70 split on the 22nd of May 2023. Based on the key measurements obtained from Adamis Pharma's financial statements, Adamis Pharma is not in a good financial situation at the moment. It has a very high risk of going through financial straits in February.Adamis Pharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Adamis Pharma has an asset utilization ratio of 43.51 percent. This connotes that the Company is making $0.44 for each dollar of assets. An increasing asset utilization means that Adamis Pharma is more efficient with each dollar of assets it utilizes for everyday operations.Adamis Pharma Ownership Allocation
Adamis Pharma shows 7.81 percent of its outstanding shares held by insiders and 16.59 percent owned by other corporate entities.Adamis Pharma Profitability Analysis
The company reported the previous year's revenue of 4.76 M. Net Loss for the year was (26.48 M) with loss before overhead, payroll, taxes, and interest of (1.43 M).About Adamis Pharma Valuation
The delisted stock valuation mechanism determines Adamis Pharma's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Adamis Pharma based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Adamis Pharma. We calculate exposure to Adamis Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Adamis Pharma's related companies.Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California. Adamis Pharmaceuticl operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 15 people.
Adamis Pharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Adamis Pharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 149.9 M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in Adamis Stock
If you are still planning to invest in Adamis Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Adamis Pharma's history and understand the potential risks before investing.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |